Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will once again have wonderful presence at the annual American Society for Radiation Oncology meeting beginning this weekend. Congratulations to the following faculty members for their participation:
Moderator for the Pancreatic Cancer Session
Chair of the ASTRO Research Committee; Panelist on the microRNAs in Cancer Session
ASTRO Faculty Member; Member of the Annual Scientific Program Committee and the Educational Committee; Reviewed for the Gynecologic Abstracts; Co-Moderator for the Enhancing Safety Culture in Radiation Oncology Session
Chair of The ASTRO Breast Abstract Panel Committee
Chair and Panelist for the microRNAs in Cancer Session
Vice Chair of the ASTRO Scientific Program Committee; Moderator and Invited Speaker for the ARRO Career Seminar; Moderator for the Clinical Trials Session; Moderator for the Press Conference highlighting the top four research breakthroughs from the conference; and Participant in the Meet the Professor Session
Moderator for the Outcomes and Health Service Research, Palliative Care, and Quality of Life Session
Poster Presentation -
A Comparative Analysis Between 3D Non-coplanar Beam Technique (NCBT) versus Single-isocenter Multi-segment Conformal Arc (SiMs) Technique for Liver Stereotactic Body Radiotherapy (SBRT)
Educational Session - Stereotactic Body Radiotherapy: Clinical and Biological Update
Oral Presentation -
Prognostic Value of p16 Expression in Laryngeal Cancer Patients Treated with Radiation
Poster Presentation - Role of Excision Repair Cross Complementation 1 Expression as a Prognostic Marker for Response to Radiotherapy in Early Stage Laryngeal Cancer
Oral Presentation -Mechanism of Radiation Sensitization by Inhibitors Poly(ADP-ribose) Polymerase (PARP)
Oral Presentation - Hypoxia and microRNAs in Cancer Biology
Poster Presentation -
Head and Neck Cancer (HNC) Patients Undergoing Intensity Modulated Radiation Therapy (IMRT) Have Fewer Subsequent Days of Hospitalization (DOH) than Do Patients Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database.C.P. Gross, P.M. Soulos, R. Sharma, D.V. Makarov, R.H. Decker, B.D. Smith, R.A. Desai, L. Cramer, J.B. Yu.
Poster Presentation - Temporal Trends in the Treatment of Elderly Men with Low and Moderate Risk Prostate Cancer: The Effect of Life Expectancy on the Administration of Curative Therapy
A.C. Raldow, R. Sharma, C. Presley, L. Cramer, J.B. Yu, P. Soulos, C.P. Gross.
Poster Presentation - Postoperative Vaginal Brachytherapy Alone (VB) Provides Equally Effective Treatment With Less Toxicity Than External Beam Radiation and Vaginal Brachytherapy (EXT + VB) In The Treatment of Stage II Endometrial Adenocarcinoma.SL Galper, J Harrington, E Ratner, Y Deng, D Zelterman, P Hui, TJ Rutherford, SA Higgins.
Educational Session - Cancer as a Chronic Illness
- Breast Cancer Management: Early Stage Disease
Panel Session - Physician Self-Referral and Radiation Oncology: Curable Problem or Fatal Affliction?
Best of ASTRO
Poster Presentation - Head and Neck Cancer (HNC) Patients Undergoing Primary Radiation with Intensity Modulated Radiation Therapy (IMRT) Demonstrate Improved Overall Survival (OS) Compared to Those Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database
I am pleased to welcome Daniel Morgensztern to Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven.
Daniel's clinical expertise in lung cancer and experience in clinical trial development will continue to strengthen our ability to offer the most advanced treatments to our patients.
Dr. Morgensztern is an Assistant Professor of Medical Oncology and will join the Yale Cancer Center Developmental Therapeutics Research Program.
In addition, he will be the physician director for the Smilow 12 inpatient unit for patients with solid tumors.
Yale Cancer Center Research Prize and Award for Clinical Excellence
Yale Cancer Center is pleased to announce two annual, competitive awards in the areas of excellence in research and clinical care.Each award will be announced at the Yale Cancer Center Conclave to be held on Monday, November 22, 2010.
Yale Cancer Center Research Prize:
This award is in support of excellence in the areas of basic science, translational research, clinical research, cancer prevention and control, epidemiological research, or case review.
It will be awarded to the Cancer Center investigator whose paper is considered to have had the greatest impact on their field this year.
Yale Cancer Center Award for Clinical Excellence:
This award will be given to the physician who best exemplifies excellence in clinical care including superb clinical skills, use of a patient and family centered approach to care, and inclusion of a multi-disciplinary care model.
Deadline Monday: American Cancer Society Institutional Research Grant
Yale Cancer Center is pleased to announce a competition for grants for new Yale Assistant Professors.
The awards are to support innovative work in the broad field of basic, translational, clinical, and prevention/control cancer research by new investigators.
These grants are restricted to investigators who have not already received federal research grant support or a previous ACS-IRG award. One-year grants will provide up to $40,000 for each project. Yale Cancer Center members and non-members are encouraged to apply.
For more information, please contact Jan Zulkeski
Julie Ann Sosa, MD was an invited speaker to present, Randomized Phase 2/3 Trial of a Tumor Vascular Disrupting Agent Fosbretabulin (CA4P) with Carboplatin and Paclitaxel in Anaplastic Thyroid Cancer: Interim Safety and Efficacy Results of the FACT Trial, earlier this month at the European Society of Medical Oncology in Milan, Italy. Yale was the second highest accruing center to this trial in the world.
Howard Hochster, MD
will be running the NYC Marathon on November 7th (his 19th time!) to raise money for Team Continuum, a cancer charity founded by a cancer survivor to assist patients undergoing chemotherapy with their needs not covered by the medical system. Team Continuum will have about 250 runners this year and YCC/Smilow is submitting a grant to support families of patients with long-term stays and patient-navigators.
Anyone wishing to support this charity through Dr. Hochster's run can donate here.
D was an invited speaker at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany to present Second Malignancies after Hodgkin's Lymphoma : The Thirty-Five Year Yale University Experience. Coauthors from Yale included: Kenneth B. Roberts, MD, Bilal Olmer, MD, Carolyn Demsky, APRN, Rong Wang, BS, Gary Kupfer, MD, PhD, Dennis Cooper, MD, Stuart Seropian, MD, Nina S. Kadan-Lottick, MD, MPH, and Xiaomei Ma, PhD. The study showed that with the change in managing Hodgkin Lymphoma from radical radiotherapy to combined chemotherapy using less alkylating agents and low-dose involved-field radiotherapy, there has been a marked reduction in secondary cancers.
Melinda Irwin, PhD
has been awarded a $150k grant from the American Institute for Cancer Research to do a weight loss trial in women with breast cancer.The title of the project is Telephone vs. In-Person Weight Loss Counseling on Weight, Body Fat, and Serum Markers in Breast Cancer Survivors.
, PhD, Assistant Professor of Therapeutic Radiology, in the section of Radiological Physics, recently returned from the meeting of the Radiation Research Society in Maui. David was an invited speaker in a symposium at that meeting, where he presented a paper entitled, Using Monte Carlo DNA damage simulations and deterministic repair models to examine the putative mechanisms of radiation-induced cell death. This paper was based on and extended David's work that won last year's Radiation Research Society's Editors' Award for the outstanding paper published by a young investigator in Radiation Research.
Howard Hochster, MD presented a poster at the NCI-ASCO-EORTC meeting last week, entitled A Dose Finding and Phase II Study of the MEK-inhibitor Selumetinib (AZD6244) and Irinotecan as Second Line Therapy in Patients with KRAS or BRAF-mutated Colorectal Cancer.
Primary trastuzumab resistance: new tricks for an old drug
AACR Calls for SU2C Innovative Research Grant Letters of Intent
The American Association for Cancer Research calls upon the cancer research community to submit Letters of Intent for Stand Up To Cancer's Innovative Research Grants (IRG), which support the next generation of extraordinary cancer research leaders in their quest to conquer cancer.
The grants will provide funding of up to $750,000 over a three-year period.
IRGs offer financial support to scientists pursuing novel, high-risk, but potentially high-reward cancer research proposals that have significant potential for translational application and hold great promise for advancing SU2C's overarching goal of improving and saving lives. Proposals may focus on any discipline within basic, translational or clinical research, provided that these criteria are met.
Letter of Intent Deadline: 12:00 p.m. ET on Monday, Nov. 15, 2010.
Learn More >>
Sidney Kimmel Foundation Translational Science Award
The foundation provides these awards specifically for physicians engaged in translational science. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application to subsequent human investigation.
Sidney Kimmel Foundation for Cancer Research Scholars Award
Each year the Kimmel Foundation expects to select up to ten grant recipients for the Scholars Award who will receive $100,000 per year for two years. Qualified applicants must hold an MD, PhD, or equivalent graduate degree and must perform research in an American not-for-profit institution during the period of Kimmel Foundation support.
The Kimmel Foundation is seeking accomplished young investigators dedicated to a career in cancer research. Applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July, 2007.
Doris Duke Charitable Foundation Clinical Scientist Development Award
For assistant professors with an MD or MD/PhD working in any disease area as they begin their careers as independent clinical researchers. Candidates must have been appointed to their first full-time faculty level position between January 1, 2006 and January 1, 2011. At least 75% of professional time must be devoted to research, overall. $150,000 per year direct costs for 3 years.
Grants distributed from Alex's Lemonade Stand Foundation are designed to fill critical voids in current pediatric cancer research. Innovation, Young Investigator, and Program Innovation Awards are available.
Letter of Intent Deadline: December 1, 2010
New Faculty Recruits
Please submit your recent publication and grant announcements to: